Under the terms of the Agreement, MolecuLight ® Inc. will support preclinical and clinical research led by Dr. Ralph DaCosta, a Scientist at the Princess Margaret Cancer Center and Techna Institute, and Founder and Chief Scientific Officer of MolecuLight ® Inc. The focus of the different research projects is to investigate the various bacterial species detected via autofluorescence imaging and to further explore the impact of the technology in the clinic.

Posted on November 07 , 2014

MolecuLight ® Inc. (Toronto, Canada) announced today a multi-project based research agreement with the University Health Network (UHN, Toronto, Canada) aimed at advancing their new handheld optical imaging technology enabling real-time bacterial imaging in wounds at the point-of-care.

Under the terms of the Agreement, MolecuLight ® Inc. will support preclinical and clinical research led by Dr. Ralph DaCosta, a Scientist at the Princess Margaret Cancer Center and Techna Institute, and Founder and Chief Scientific Officer of MolecuLight ® Inc. The focus of the different research projects is to investigate the various bacterial species detected via autofluorescence imaging and to further explore the impact of the technology in the clinic.

Dr DaCosta adds: “A UHN-MolecuLight ® Inc. collaboration allows us to significantly expand the current application areas based on our proprietary fluorescence imaging technology platform. The translational focus of our lab and our track record of medical device innovation links with MolecuLight ® Inc.’s vision of delivering unprecedented evidence-based products to the clinical market to improve the care and quality of life of patients suffering from acute and chronic wounds while significantly building shareholder value”.

Craig Kennedy, CEO of MolecuLight ® Inc., comments: “We are very happy to get this opportunity to continue working directly with the company’s founder Dr. DaCosta and collaborate with a world-class research organization like UHN. We really believe that our technology has the potential to change the standard of wound care today while significantly building shareholder value”.

University Health Network includes Toronto General and Toronto Western Hospitals, Princess Margaret Cancer Centre, and Toronto Rehabilitation Institute. The scope of research and complexity of cases at University Health Network has made it a national and international source for discovery, education and patient care. It has the largest hospital-based research program in Canada, with major research in cardiology, transplantation, neurosciences, oncology, surgical innovation, infectious diseases, genomic medicine and rehabilitation medicine. University Health Network is a research hospital affiliated with the University of Toronto. www.uhn.ca